Featured Research

from universities, journals, and other organizations

Halting A Pandemic: NIH Mounts Search For A H1N1 Vaccine

Date:
July 24, 2009
Source:
Saint Louis University Medical Center
Summary:
Bracing for an outbreak of 2009 H1N1 (swine-origin) flu that an infectious diseases expert estimates could sicken one in five people this fall, scientists are launching a series of clinical trials this summer to test vaccines to protect against the illness. "It's looking more and more like we're going to have a big flu outbreak this fall as soon as the kids get back to school. Influenza is unpredictable, but I believe this pandemic will hit pre-teens, teens and their parents hard, and as many as 60 million Americans could be sick with the flu," according to one expert.

Bracing for an outbreak of 2009 H1N1 (swine-origin) flu that a Saint Louis University infectious diseases expert estimates could sicken one in five people this fall, scientists at eight Vaccine and Treatment Evaluation Units funded by the National Institutes of Health (NIH) are launching a series of clinical trials this summer to test vaccines to protect against the illness.

“Efforts to find an effective vaccine against H1N1 influenza are historic,” said Sharon Frey, M.D., professor of infectious diseases at Saint Louis University School of Medicine and lead investigator for one of the national research studies.

“Scientists very quickly identified the flu virus, industry rapidly responded by making vaccine and multiple clinical trials to test vaccine are ramping up. Researchers are pouring a tremendous amount of effort and resources into delivering a safe and effective vaccine to the American public as quickly as possible.”

Frey, who is also on faculty at the Center for Vaccine Development at Saint Louis University, is a member of the team of infectious diseases researchers whose work will help scientists and public health officials develop the best strategy to protect Americans against 2009 H1N1 influenza.

“It’s looking more and more like we’re going to have a big flu outbreak this fall as soon as the kids get back to school. Influenza is unpredictable, but I believe this pandemic will hit pre-teens, teens and their parents hard, and as many as 60 million Americans could be sick with the flu. It’s critical that we find a way to protect people from this disease,” said Robert Belshe, M.D., director of the Center for Vaccine Development at Saint Louis University School of Medicine and a co- investigator for several of the national research studies.

"The modelers predict the peak will be in October, which means we’ll see more H1N1 influenza in September. We’ll be in the midst of it before we know it.”

The United States government declared the H1N1 influenza a public health emergency in April and two months later, the World Health Organization classified the H1N1 influenza as a pandemic, which reflects the widespread nature of the outbreak.

“So far, most of the infections are relatively mild. We’re hoping it’s going to stay that way, but we don’t really know,” Belshe said. “With the large number of people who are predicted to become infected, the number of serious health complications and even deaths could soar.”

This round of research studies will recruit thousands of healthy volunteers nationally to test the safety and measure the body’s immune response to an investigational H1N1 flu vaccine. They will include adult, pediatric and elderly volunteers.

Eight Vaccine and Treatment Evaluation Units (VTEUs) which are funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, will participate in these trials. In addition to the VTEU at Saint Louis University, the VTEU sites are Baylor College of Medicine; Emory University; University of Maryland School of Medicine in Baltimore; Children’s Hospital Medical Center in Cincinnati; Group Health Cooperative in Seattle; University of Iowa; and Vanderbilt University. They will be joined by Duke University Medical Center and Children’s Mercy Hospital in Kansas City.

Frey will lead the team of investigators who will study whether an experimental H1N1 influenza vaccine, which is not formulated to protect against the traditional seasonal flu, can be given with the seasonal influenza vaccine. http://clinicaltrials.gov/show/NCT00943878

The answer to that question is important, Frey said, because experts are predicting that both strains of influenza will circulate for much of the fall and winter. The studies will analyze potential problems of giving the vaccines together, such as whether one vaccine will undermine the protective power of the other.

In other H1N1 influenza trials, VTEU researchers will compare the immune response to different numbers of doses and different strengths of the H1N1 flu vaccine to see which is more effective. http://clinicaltrials.gov/show/NCT00943488 and http://clinicaltrials.gov/show/NCT00943631

NIAID-funded investigators are currently studying giving the common seasonal flu vaccine to pregnant women to get some baseline data for future comparisons they can use as they research giving the H1N1 vaccine to pregnant women. http://www.clinicaltrial.gov/ct2/show/NCT00905125?term=pregnancy+influenza&rank=5

Typically, vaccines are the most powerful weapon against influenza. About two or three weeks after getting the flu vaccine, the body mounts an immune response and makes antibodies that fight the flu virus. Those who are vaccinated may not get sick if they are exposed to influenza or may have a much milder or shorter case of the illness.

“Since vaccines work well to protect against the seasonal flu, we believe that an effective vaccine against 2009 H1N1 flu will help to control this pandemic,” Belshe said.

“But because we are predicting the H1N1 flu will hit sooner than the seasonal flu, which typically strikes between October and March and peaks in February, time is of the essence as we conduct our vaccine research.”

The H1N1 vaccine research soon will be expanded to include children. Frey added that pregnant women and those individuals who have underlying illnesses of the kidneys, liver, heart and lungs (including asthma) will face the biggest health danger from the 2009 H1N1 influenza.


Story Source:

The above story is based on materials provided by Saint Louis University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Saint Louis University Medical Center. "Halting A Pandemic: NIH Mounts Search For A H1N1 Vaccine." ScienceDaily. ScienceDaily, 24 July 2009. <www.sciencedaily.com/releases/2009/07/090723194958.htm>.
Saint Louis University Medical Center. (2009, July 24). Halting A Pandemic: NIH Mounts Search For A H1N1 Vaccine. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/07/090723194958.htm
Saint Louis University Medical Center. "Halting A Pandemic: NIH Mounts Search For A H1N1 Vaccine." ScienceDaily. www.sciencedaily.com/releases/2009/07/090723194958.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins